Trametinib

Drug Profile

Trametinib

Alternative Names: 1120212; GSK-1120212; GSK-1120212B; JTP-74057; Mekinist; TMT 212

Latest Information Update: 14 Feb 2017

Price : $50

At a glance

  • Originator Japan Tobacco
  • Developer Dana-Farber Cancer Institute; GlaxoSmithKline; Japan Tobacco; National Cancer Institute (USA); Novartis; Pfizer; University of Texas M. D. Anderson Cancer Center
  • Class 2 ring heterocyclic compounds; Amides; Antineoplastics; Cyclopropanes; Fluorobenzenes; Iodobenzenes; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action MAP kinase kinase 1 inhibitors; MAP kinase kinase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Malignant melanoma
  • Phase II Acute myeloid leukaemia; Biliary cancer; Brain metastases; Breast cancer; Cancer; Cervical cancer; Endometrial cancer; Multiple myeloma; Non-small cell lung cancer; Pancreatic cancer; Uveal melanoma
  • Phase I/II Colorectal cancer; Solid tumours
  • Phase I Lymphoma; Mesothelioma
  • No development reported Leukaemia
  • Discontinued Inflammation

Most Recent Events

  • 25 Jan 2017 GlaxoSmithKline withdraws a phase I trial prior to enrollment due to change in strategy for Malignant melanoma (Late-stage disease, Metastatic disease, Combination therapy) in China (NCT02447939)
  • 25 Jan 2017 GlaxoSmithKline withdraws prior to enrolment a phase I trial for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (PO, Tablet) (NCT02939846)
  • 23 Dec 2016 Novartis and Ligand Pharmaceuticals enter into global license and supply agreements for the development and commercialisation of oral liquid formulation of trametinib
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top